Tag Archives: Peptides

Peptides could revolutionize medicine, yet their journey to FDA approval faces obstacles. The FDA’s slow-moving process, while claiming public safety, often acts as a gatekeeper that stalls innovation. The marketplace eagerly anticipates these therapies, but the FDA’s deliberate pace conveniently aligns with entrenched interests.